CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments (2015 - 2026)

CytomX Therapeutics has reported Change in Acquisitions & Divestments for 12 years, with the latest figure at $50.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 0.99% year-over-year to $50.0 million; the trailing twelve-month figure through Mar 2026 stood at $132.5 million (down 49.23% YoY), and the FY2025 full-year result was $133.0 million, down 47.95% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $50.0 million, up from $30.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $125.0 million in Q4 2023, with the low at $20.0 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $62.6 million across 5 years, with a median of $50.0 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments rose 25.0% — and 2025, when it slumped 71.74%.
• CytomX Therapeutics' Change in Acquisitions & Divestments stood at $100.0 million in 2022, then climbed by 25.0% to $125.0 million in 2023, then plunged by 48.0% to $65.0 million in 2024, then sank by 53.85% to $30.0 million in 2025, then soared by 66.67% to $50.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $50.0 million (Q1 2026), $30.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.